Formycon reports higher H1 revenue, narrows EBITDA loss

Formycon reported H1 2026 revenue of EUR 25.8M, sharply up y/y, while narrowing its EBITDA loss to EUR 3.4M (improved profitability on higher revenue and lower R&D). The company kept full-year 2026 revenue guidance at EUR 60M–EUR 70M and expects Group EBITDA of EUR 0M–EUR 10M. Revenue growth was driven by FYB206 milestone/upfront payments and higher royalty/milestone receipts from FYB202, with FYB206 clinical development completed and second-half results expected to rely on milestones and FYB202 royalties.

Analysis

This print is more about revenue quality than growth. When a biotech’s top line is being padded by partner-funded milestones and royalties, the market should discount the quarter unless it can see a credible bridge to recurring, self-funded earnings; otherwise the apparent margin improvement is mostly timing and accounting leverage, not a true step-change in franchise value. The key implication is that the stock can rerate only modestly until investors believe the company has passed from development optionality into a repeatable commercialization stream.

Second-order, the beneficiary is the partnered biosimilar model itself: companies that can offload development risk and monetize with upfronts/royalties should screen better than pure cash-burn developers. But the flip side is that any slip in partner execution, pricing, or launch timing will hit reported results quickly because the mix is lumpy and concentrated; that creates more earnings volatility than the headline guidance range implies. Lower R&D spend is also not a permanent tailwind if the pipeline advances again next year.

Contrarian view: the market may be underweight the possibility that this is a quality-of-earnings trap. If the second half depends on milestone timing, the guidance can hold while cash conversion disappoints, which would cap multiple expansion. The thesis is falsified if 2H milestone and royalty receipts arrive on schedule and cash burn trends toward breakeven; if not, any rally should fade over the next 1-3 months rather than become a multi-quarter re-rating.

Key Decisions for Investors

• No immediate directional trade in Formycon/SKHYV; treat the print as a watch item, not a catalyst, until 2H milestone receipts and royalty cadence are independently visible.
• If the stock trades up on the release, fade strength rather than chase it; this is a de-risking event, and upside is likely capped unless the next two quarters show repeatable cash conversion.
• Set an alert for any 2H guidance update or quarterly cash-flow disclosure that shows milestone dependence falling and operating cash burn approaching breakeven; that would be the cleanest entry point for a tactical long.
• For relative value, prefer commercial biosimilar/royalty collectors over pure development-stage biotech exposure; the better trade is a quality-of-earnings filter, not a bullish call on the sector beta.